Login to Your Account



Biogen's Heart Drug Aimed at Renal Patients Enters Phase III

By Catherine Hollingsworth


Monday, August 25, 2008
Biogen Idec Inc. enrolled the first subject in its Phase III trial of injectable Adentri, which is being tested in a group that is considered particularly hard to treat: patients with worsening heart failure and poor kidney function. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription